Related references
Note: Only part of the references are listed.Response and Resistance to BCR-ABL1-Targeted Therapies
Theodore P. Braun et al.
CANCER CELL (2020)
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
Chodimella Chandrasekhar et al.
SCIENTIFIC REPORTS (2019)
The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia
Panagiota S. Georgoulia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2019)
Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives
Marie Laurent et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Joseph Schoepfer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Drug Resistance Driven by Cancer Stem Cells and Their Niche
Marta Prieto-Vila et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Atomic view of the energy landscape in the allosteric regulation of Abl kinase
Tamjeed Saleh- et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors
Swapna Kamasani et al.
TUMOR BIOLOGY (2017)
Atomic view of the energy landscape in the allosteric regulation of Abl kinase
Tamjeed Saleh- et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Using ancient protein kinases to unravel a modern cancer drug's mechanism
C. Wilson et al.
SCIENCE (2015)
A dynamically coupled allosteric network underlies binding cooperativity in Src kinase
Zachariah H. Foda et al.
NATURE COMMUNICATIONS (2015)
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics
Silvia Lovera et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Elzbieta Gocek et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2014)
Deregulation of cell signaling in cancer
Filippo G. Giancotti
FEBS LETTERS (2014)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Simona Soverini et al.
LEUKEMIA RESEARCH (2014)
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases
Roman V. Agafonov et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy
Don L. Gibbons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
Elias J. Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
The background, discovery and clinical development of BCR-ABL inhibitors
Gemma K. Lambert et al.
DRUG DISCOVERY TODAY (2013)
Role of ABL family kinases in cancer: from leukaemia to solid tumours
Emileigh K. Greuber et al.
NATURE REVIEWS CANCER (2013)
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance
Oliver Hantschel
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The Different Flexibility of c-Src and c-Abl Kinases Regulates the Accessibility of a Druggable Inactive Conformation
Silvia Lovera et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Mechanisms of drug resistance in kinases
Rina Barouch-Bentov et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Mechanisms of acquired resistance to tyrosine kinase inhibitors
Yi-fan Chen et al.
ACTA PHARMACEUTICA SINICA B (2011)
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
D. Bixby et al.
Hematology-American Society of Hematology Education Program (2009)
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells
Audrey Sirvent et al.
BIOLOGY OF THE CELL (2008)
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Jamshid S. Khorashad et al.
BLOOD (2008)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty
Markus A. Seeliger et al.
STRUCTURE (2007)
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Sandra W. Cowan-Jacob et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mohammad Azam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A Src-like inactive conformation in the Abl tyrosine kinase domain
Nicholas M. Levinson et al.
PLOS BIOLOGY (2006)
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething et al.
LEUKEMIA (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
AS Corbin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Share Paper
